FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2122532904> ?p ?o ?g. }

• W2122532904 endingPage "1078" @default.
• W2122532904 startingPage "1071" @default.
• W2122532904 abstract "Ex vivo-generated autologous tolerogenic dendritic cells [tolDCs] can restore immune tolerance in experimental colitis. The aim of this study was to determine the safety and tolerability of administration of autologous tolDCs in refractory Crohn’s disease [CD] patients. A phase-I, single-centre, sequential-cohorts, dose-range study was designed. Stable tolDCs were generated ex vivo from monocytes following a previously developed protocol, and administered by sonography-guided intraperitoneal injection. Six sequential refractory-CD cohorts were established: the first three cohorts received a single intraperitoneal injection of tolDCs at escalating doses [2 x 106/5 x 106/10 x 106]; and the last three cohorts received three biweekly intraperitoneal injections at same escalating doses. Safety was sequentially evaluated. Patients were assessed from week 0 to 12 and followed up for 1-year period for safety. Nine patients were included. No adverse effects were detected during tolDC injection or follow-up. Three patients withdrew from the study due to CD worsening. Crohn’s Disease Activity Index [CDAI] decreased from 274 [60] {mean (standard deviation [SD])} to 222 [113] [p = 0.3]; one [11%] patient reached clinical remission [CDAI < 150] and two [22%] clinical response [CDAI decrease ≥ 100]. Crohn's Disease Endoscopic Index of Severity [CDEIS] decreased from 18 [5] to 13 [8] [p = 0.4]; lesions improved markedly in three patients [33%]. Quality of life (inflammatory bowel disease questionnaire [IBDQ]) changed from 125 [27] to 131 [38] [p = 0.7]; remission [IBDQ at Week 12 ≥ 170] was reached in one [11%] case and response [IBDQ score increase ≥ 16] in two [22%]. Intraperitoneal administration of autologous tolDCs appears safe and feasible in refractory CD patients. Further studies should be developed to test clinical benefit, determine the optimal administration route and dose, and monitor the immune responses; See [www.eudract.ema.europa.eu, EudraCT number 2007-003469-42; www.aemps.gob.es number PEI 08-049]." @default.
• W2122532904 created "2016-06-24" @default.
• W2122532904 creator A5001147618 @default.
• W2122532904 creator A5010303736 @default.
• W2122532904 creator A5014069545 @default.
• W2122532904 creator A5015665559 @default.
• W2122532904 creator A5016235381 @default.
• W2122532904 creator A5018652145 @default.
• W2122532904 creator A5022806186 @default.
• W2122532904 creator A5040354010 @default.
• W2122532904 creator A5041478981 @default.
• W2122532904 creator A5046982259 @default.
• W2122532904 creator A5048248914 @default.
• W2122532904 creator A5071264946 @default.
• W2122532904 creator A5076786150 @default.
• W2122532904 creator A5080119173 @default.
• W2122532904 creator A5086449665 @default.
• W2122532904 date "2015-08-24" @default.
• W2122532904 modified "2023-10-17" @default.
• W2122532904 title "Intraperitoneal Administration of Autologous Tolerogenic Dendritic Cells for Refractory Crohn’s Disease: A Phase I Study" @default.
• W2122532904 cites W1607808246 @default.
• W2122532904 cites W1840927757 @default.
• W2122532904 cites W1970596945 @default.
• W2122532904 cites W1979351468 @default.
• W2122532904 cites W1984127959 @default.
• W2122532904 cites W2030479446 @default.
• W2122532904 cites W2036500213 @default.
• W2122532904 cites W2050216284 @default.
• W2122532904 cites W2062512887 @default.
• W2122532904 cites W2074958963 @default.
• W2122532904 cites W2087727538 @default.
• W2122532904 cites W2088803695 @default.
• W2122532904 cites W2105211854 @default.
• W2122532904 cites W2105734762 @default.
• W2122532904 cites W2116432220 @default.
• W2122532904 cites W2117477752 @default.
• W2122532904 cites W2141654978 @default.
• W2122532904 cites W2149532284 @default.
• W2122532904 cites W2151088711 @default.
• W2122532904 cites W2170876743 @default.
• W2122532904 cites W2171484002 @default.
• W2122532904 cites W2323691552 @default.
• W2122532904 cites W2328281435 @default.
• W2122532904 cites W2332451323 @default.
• W2122532904 cites W3149527659 @default.
• W2122532904 doi "https://doi.org/10.1093/ecco-jcc/jjv144" @default.
• W2122532904 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26303633" @default.
• W2122532904 hasPublicationYear "2015" @default.
• W2122532904 type Work @default.
• W2122532904 sameAs 2122532904 @default.
• W2122532904 citedByCount "121" @default.
• W2122532904 countsByYear W21225329042015 @default.
• W2122532904 countsByYear W21225329042016 @default.
• W2122532904 countsByYear W21225329042017 @default.
• W2122532904 countsByYear W21225329042018 @default.
• W2122532904 countsByYear W21225329042019 @default.
• W2122532904 countsByYear W21225329042020 @default.
• W2122532904 countsByYear W21225329042021 @default.
• W2122532904 countsByYear W21225329042022 @default.
• W2122532904 countsByYear W21225329042023 @default.
• W2122532904 crossrefType "journal-article" @default.
• W2122532904 hasAuthorship W2122532904A5001147618 @default.
• W2122532904 hasAuthorship W2122532904A5010303736 @default.
• W2122532904 hasAuthorship W2122532904A5014069545 @default.
• W2122532904 hasAuthorship W2122532904A5015665559 @default.
• W2122532904 hasAuthorship W2122532904A5016235381 @default.
• W2122532904 hasAuthorship W2122532904A5018652145 @default.
• W2122532904 hasAuthorship W2122532904A5022806186 @default.
• W2122532904 hasAuthorship W2122532904A5040354010 @default.
• W2122532904 hasAuthorship W2122532904A5041478981 @default.
• W2122532904 hasAuthorship W2122532904A5046982259 @default.
• W2122532904 hasAuthorship W2122532904A5048248914 @default.
• W2122532904 hasAuthorship W2122532904A5071264946 @default.
• W2122532904 hasAuthorship W2122532904A5076786150 @default.
• W2122532904 hasAuthorship W2122532904A5080119173 @default.
• W2122532904 hasAuthorship W2122532904A5086449665 @default.
• W2122532904 hasBestOaLocation W21225329041 @default.
• W2122532904 hasConcept C121332964 @default.
• W2122532904 hasConcept C126322002 @default.
• W2122532904 hasConcept C141071460 @default.
• W2122532904 hasConcept C142424586 @default.
• W2122532904 hasConcept C150903083 @default.
• W2122532904 hasConcept C197934379 @default.
• W2122532904 hasConcept C207001950 @default.
• W2122532904 hasConcept C26291073 @default.
• W2122532904 hasConcept C2778260677 @default.
• W2122532904 hasConcept C2778375690 @default.
• W2122532904 hasConcept C2779134260 @default.
• W2122532904 hasConcept C2779280984 @default.
• W2122532904 hasConcept C71924100 @default.
• W2122532904 hasConcept C86803240 @default.
• W2122532904 hasConcept C87355193 @default.
• W2122532904 hasConcept C90924648 @default.
• W2122532904 hasConceptScore W2122532904C121332964 @default.
• W2122532904 hasConceptScore W2122532904C126322002 @default.
• W2122532904 hasConceptScore W2122532904C141071460 @default.
• W2122532904 hasConceptScore W2122532904C142424586 @default.
• W2122532904 hasConceptScore W2122532904C150903083 @default.

• next